Immuneel Therapeutics, the Bengaluru-based cell and gene therapy company, has raised over Rs 100 crore (approximately $10.5 million) in a Series B round, as publicly reported on June 8, 2026. The round draws participation from a mix of new and existing backers, with no single lead investor publicly disclosed. Total lifetime funding for the company now stands at over $40 million.
Quick Highlights
- Founders: Kiran Mazumdar-Shaw, Siddhartha Mukherjee, Kush Parwar
- Participating Investors: Singularity AMC, Rainmatter by Zerodha, Kiran Mazumdar-Shaw (existing), Eight Roads Ventures (existing), F-Prime Capital (existing), and high-net-worth individuals
- Investor Background: Backers span life-sciences-focused funds, fintech-aligned venture arms, and global healthcare investors
- Headquarters: Bengaluru, Karnataka, India
- Announcement Date: June 8, 2026
Funding Breakdown
Use of Funds
The Series B capital will primarily be deployed to scale GMP (Good Manufacturing Practice) manufacturing capacity for Qartemi — India’s first approved CAR-T therapy, indicated for Non-Hodgkin Lymphoma and leukemia. Funds will also support commercialisation of Qartemi, advance Immuneel’s next-generation cell and gene therapy pipeline, and accelerate entry into international markets across Asia-Pacific and the Middle East.
Funding Timeline
This Series B is the most recent disclosed milestone in Immuneel’s capital journey. With this round, total lifetime funding for the company has crossed $40 million, according to public filings and reports.
Expansion Plans
Immuneel intends to extend its commercial footprint beyond India, targeting the Asia-Pacific region and the Middle East as priority international markets. These geographies represent significant unmet need in advanced oncology treatments, where CAR-T therapies remain scarce and largely import-dependent.
Significance
Immuneel’s Series B is a landmark moment for India’s deep-tech biotech sector — it represents meaningful institutional confidence in a domestic CAR-T platform at a time when most such therapies in the region are imported at prohibitive cost. The backing of Biocon founder Kiran Mazumdar-Shaw alongside global healthcare-focused funds signals that India-originated cell and gene therapy is attracting serious, long-term capital. For patients, scaling Qartemi’s manufacturing capacity could directly improve access and affordability of a life-saving oncology treatment. The round also reinforces a broader trend of India moving up the biotech value chain, from generics manufacturing toward proprietary biologics and advanced therapies.
Nobel Hygiene: IPO Preparation Underway
In a separate development reported on June 6, 2026, Nobel Hygiene — a Quadria Capital-backed adult diaper and personal hygiene brand — has converted to a public company structure, signalling a formal move toward an IPO. No fundraise amount or valuation has been disclosed in connection with this conversion.
Significance
Nobel Hygiene’s corporate restructuring reflects the maturing trajectory of India’s consumer health and FMCG ecosystem, where private-equity-backed brands are increasingly pursuing public listings as an exit and growth pathway. The adult incontinence and hygiene category remains underpenetrated in India relative to global benchmarks, and a successful IPO would provide Nobel Hygiene with public capital to compete at scale. However, given that this event is currently supported by a single source, readers should treat specific details with appropriate caution until independently confirmed.
Note: The Immuneel Therapeutics funding details have been verified against multiple publicly available reports as of June 8, 2026. The Nobel Hygiene IPO preparation report is single-source and could not be independently confirmed at the time of publication.
Stay current with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
